Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure
rates exceeding 90% in children, it remains an important cause of morbidity and mortality in …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy
characterized by aberrant proliferation of immature thymocytes. Despite an overall survival …

Pan-cancer analyses that examine commonalities and differences among various cancer
types have emerged as a powerful way to obtain novel insights into cancer biology. Here we …

Purpose Somatic deletions that affect the lymphoid transcription factor–coding gene IKZF1
have previously been reported as independently associated with a poor prognosis in …

Drug sensitivity and resistance testing on diagnostic leukemia samples should provide
important functional information to guide actionable target and biomarker discovery. We …

Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of childhood
cancer-related death. Prior studies have shown clonal mutations at relapse often arise from …

T-cell acute lymphoblastic leukemias (T-ALL) are immature lymphoid tumors localizing in the
bone marrow, mediastinum, central nervous system, and lymphoid organs. They account for …

FLT3 mutations are prevalent in AML patients and confer poor prognosis. Crenolanib, a
potent type I pan-FLT3 inhibitor, is effective against both internal tandem duplications and …

Although multiagent combination chemotherapy is curative in a significant fraction of
childhood acute lymphoblastic leukemia (ALL) patients, 20% of cases relapse and most die …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and constitutes
approximately 25% of cancer diagnoses among children under the age of 15 (Howlader et …